MSC.sTRAIL Has Better Efficacy than MSC.FL-TRAIL and in Combination with AKTi Blocks Pro-Metastatic Cytokine Production in Prostate Cancer Cells

MSC.sTRAIL Has Better Efficacy than MSC.FL-TRAIL and in Combination with AKTi Blocks Pro-Metastatic Cytokine Production in Prostate Cancer Cells

Cell therapy is a promising new treatment option for cancer. In particular, mesenchymal stem cells (MSCs) have shown potential in delivering therapeutic genes in various tumour models and are now on the verge of being tested in the clinic. A number of therapeutic genes have been examined in this con...

Full description

Bibliographic Details
Main Authors: Andrea Mohr, Tianyuan Chu, Greg N. Brooke, Ralf M. Zwacka
Format: Article
Language:English
Published: MDPI AG 2019-04-01
Series:Cancers
Subjects:
mesenchymal stem cells
cell therapy
sTRAIL
prostate cancer
AKT
AKTi
IL-6
CXCL5
ENA-78
Online Access:https://www.mdpi.com/2072-6694/11/4/568

Similar Items

Similar Items